secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001104659-24-107052
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics reports preclinical GT-02287 data showing disease-modifying potential in Parkinson's models
--------------------------------------------------------------------------------

- GT-02287 rescued motor and cognitive deficits in GBA1 and idiopathic PD models; effects persisted >1 week after drug withdrawal.
- GT-02287 improved mitochondrial function and reduced α-synuclein aggregation in GBA1-PD in vitro and in vivo models.
- GT-02287 reduced Tau accumulation in GBA1-mutant and wild-type cell lines, suggesting potential for Alzheimer's disease.
- Delayed GT-02287 administration restored motor function to control levels and reduced neurodegeneration markers (NfL).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924107052/0001104659-24-107052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465924107052/tm2425756d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-107052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer